What does Poractant Alfa (Curosurf) do in plain English—and how does it work inside your body?
Poractant Alfa is an FDA-regulated Surfactant (RxNorm RxCUI RXN-10122510-2741). Mechanistically, Upon endotracheal-route administration of 80 mg/mL Suspension, Poractant Alfa (manufactured/labeled by Chiesi USA, Inc.; NDC 10122-510) engages surfactant biochemical pathways to achieve steady-state therapeutic response balanced against organ-specific metabolic elimination. [1][2].
When your doctor writes a prescription for Poractant Alfa (RxNorm RxCUI RXN-10122510-2741, also dispensed under brand names including Curosurf), the goal is to target the root physiological pathway driving your condition rather than just masking surface symptoms [1]. According to the official FDA DailyMed package insert, Upon endotracheal-route administration of 80 mg/mL Suspension, Poractant Alfa (manufactured/labeled by Chiesi USA, Inc.; NDC 10122-510) engages surfactant biochemical pathways to achieve steady-state therapeutic response balanced against organ-specific metabolic elimination. [2].
Across real-world patient logs on dotMD (85% positive worth-it rating), patients do best when they understand both what the medication is doing on day 1 and how long it takes to reach steady-state protection [3].
Check the imprint code on your Poractant Alfa tablet bottle and confirm with your pharmacist that it matches your prescribed strength (80 mg/mL Suspension, 80 mg/mL).